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Abstract. Angiogenesis is an essential event during the 
excessive growth and metastatic spread of solid tumours. 
Anti-angiogenic agents have become a new choice of therapy 
for patients with cancer. In the present study, we investigated 
the potential effect of Yangzheng Xiaoji, a traditional Chinese 
medicinal formula presently used in the treatment of several 
solid tumours including liver cancer and gastric cancer, on 
angiogenesis, in vitro. The human vascular endothelial cell line 
HECV was used. A Matrigel-based sandwich tubule forma-
tion assay was employed to assess in vitro angiogenesis, a 
colorimetric method for assessing in vitro cell growth. Electric 
cell-substrate impedance sensing (ECIS) was used to evaluate 
the adhesion and migration of endothelial cells. The effects 
on activation of focal adhesion kinase (FAK) were evaluated 
using western blotting and immunofluorescence methods. 
Yangzhen Xiaoji extract DME25 significantly inhibited tube 
formation (p=0.046 vs control). This was seen together with 
a concentration-dependent inhibition on cell-matrix adhesion 
and cellular migration. It was demonstrated that the focal 
adhesion kinase (FAK) inhibitor PF557328 had a significant 
synergistic effect on DME25-induced inhibition of cell adhe-
sion, migration and tube formation. The study showed that 
DME25 inhibited the phosphorylation of FAK in endothelial 
cells. In conclusion, Yangzhen Xiaoji has a marked effect on 
angiogenesis, in vitro and that this effect is at least partly medi-
ated by the focal adhesion kinase (FAK) pathway.
Introduction
The growth of solid tumour beyond certain size and the systemic 
spread of cancer cells are dependent on the presence and degree 
of angiogenesis in the tumour (1-3). This realisation has led to 
discovery and development of anti-angiogenesis agents, both 
naturally occurring (for example endostatin, angiostatin, VEGI), 
synthetic and biological forms, for example bevacizumab and 
thalidomide. The last decade has witnessed the translation of 
anti-angiogenesis agents into clinical practice. For example, 
some of the anti-angiogenesis drugs are now almost routinely 
used on eligible patients (4-9). Some of the anti-angiogenic and 
anti-cancer compounds are either extracts from natural products 
or derivatives of natural products (7-9).
Yangzheng Xiaoji is a traditional Chinese medical formula 
that has been redeveloped in recent years and has been 
shown to have anti-cancer actions in patients with certain 
solid tumours. In a recent randomised doubled blinded study 
of patients with primary liver cancer, patients who received 
conventional chemotherapy combined with Yangzheng Xiaoji 
(n=304) showed significantly increased rate of disease remis-
sion (complete and partial remissions) compared with patients 
who received chemotherapy alone (n=103) (23.3% vs 14%, 
respectively, p<0.01) (10). In the study, patients who received 
combinational therapy also had improved quality of life, based 
on the Karnofsky method. The formula has also been reported 
to be able to improve atypical dysplasia in the stomach (11).
The mechanisms of the anti-cancer action of Yangzheng 
Xiaoji are not clear. It has been shown that patients who 
received the Yangzheng Xiaoji and chemotherapy combination 
has less bone marrow suppression compared with those who 
received chemotherapy (10). It has been suggested therefore 
that one of mechanisms underlying the clinical observations 
is that Yangzheng Xiaoji may improve the immune function 
of the body. However, if the formula has an direct effect on 
cancer cells is not clear.
In addition to the body's defence, cancer progression is also 
dependent on the biological characteristics of cancer cells, 
including the rate of cell proliferation, invasiveness, ability to 
degrade matrix and migration. Angiogenesis is also a key to 
the distant spread of cancer cells. The latter cell functions are 
also closely linked to the metastatic potential of cancer cells. 
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Naturally occurring compounds have been reported to be 
able influence a number of these cell functions. For example, 
Taxol, a plant alkaloid, was initially extracted from western 
yew bark and is a widely used chemotherapeutic agent (12,13). 
Fumagillin is also a natural product shown to be a strong anti-
angiogenic agent (8,14). Artenisinin, an compound extracted 
from Qinhao, a Chinese medical herb used in the treatment 
of malaria has also been indicated in cancer treatment (15,16).
In the present study, we report the direct effect of 
Yangzheng Xiaoji extract on in vitro angiogenesis and the 
adhesion and migration of vascular endothelial cells. With 
little effect on the growth of endothelial cells, it has a marked 
inhibitor effect on the microvessel-like tubules, cell-matrix 
adhesion and cellular migration, in a concentration dependent 
manner. Whilst the extract inhibited the phosphorylation of 
FAK, it synergistically inhibited the angiogenesis with FAK 
inhibitor.
Materials and methods
Human endothelial HECV cells were purchased from Interlab 
(Milan, Italy). The cells were maintained in Dubecco's modi-
fied Eagle's medium (DMEM) (Sigma-Aldrich, Poole, Dorset, 
UK) supplemented with penicillin, streptomycin and 10% 
foetal calf serum (Sigma-Aldrich). The cells were incubated 
at 37˚C, 5% CO2 and 95% humidity. Matrigel (reconstituted 
basement membrane) was purchased from Collaborative 
Research Products (Bedford, MA, USA). A selective small 
inhibitor to FAK (FP573228) was from Tocris (Bristol, UK). 
Antibody to Paxillin were from Transduction Laboratories 
and phospho-specific antibodies (anti-FAK, anti-pFAK and 
anti-pPaxillin) were from Santa-Cruz Biotechnologies (Santa 
Cruz, CA, USA).
Preparation of extract DME25 from Yangzheng Xiaoji for 
experimental use. Medicinal preparation of Yangzheng Xiaoji 
(Yiling Pharmaceutical, Hebei) was subject to extraction using 
DMSO, balanced salt solution and ethanol, on rotating wheel 
for 24 h at 4˚C as we recently reported (17). Insolubles were 
removed after centrifugation at 15,000 x g. DMSO prepara-
tion was found to be more consistent, reproducible and with 
better yield compared with the other two solvents. DMSO 
extract was hence used in the subsequent experiments. The 
extract was standardised by quantifying the optical density 
of the preparation using a spectrophotometer at a wavelength 
of 405 nM. A master preparation of the extract which gave 
0.25 OD was stocked as the master stock and so named as 
DME25 for the experiments.
In vitro cell growth assay. This was based on a previous 
published method (18). HECV cells were seeded into 96 well 
plates at a density of 3,000 cells/well. Triplicate plates were 
set up for incubation periods of overnight, 3 days and 5 days. 
Following sufficient incubation, the plates were removed from 
the incubator, fixed in 4% formaldehyde (v/v) and stained 
with 0.5% (w/v) crystal violet. The crystal violet stain was 
subsequently extracted using a 10% acetic acid (v/v) allowing 
the detection of cell density through spectrophotmeric analysis 
of the resulting solutions absorbance using a Bio-Tek ELx800 
multi-plate reader (Bio-Tek Instruments Inc., VT, USA).
Electric cell-substrate impedance sensing (ECIS) based 
cellular adhesion and migration assays. ECIS-Zθ instrument 
(Applied Biophysics Inc., NJ, USA) were used for cell adhesion 
and motility (wounding assay) assays in the study (19,20). Cell 
modelling was carried out using the ECIS RbA modelling soft-
ware, supplied by the manufacturer. The 96W1E ECIS arrays 
were used in the present study. ECIS measures the interaction 
between cells and the substrate to which they were attached 
via gold-film electrodes placed on the surface of culture dishes. 
Following treating the array surface with a cysteine solution, 
the arrays were incubated with complete medium for 1 h. The 
same number of the respective cells was added to each well. 
In the cell adhesion assay, the adhesion was tracked immedi-
ately after adding the cells into the arrays. For cell migration 
assay, the arrays with cells were allowed to reach confluence 
after 3 h. The monolayer of the cells was electrically wounded 
at 2,000 mA for 20 sec. Impedance and resistance of the cell 
layer were immediately recorded for a period of up to 20 h. For 
signalling transduction inhibitor assays, the respective inhibi-
tors was included in the wells. Adhesion and migration were 
modelled using the ECIS RbA cell modelling software as we 
recently reported (21,22).
In vitro tubule formation assay. In vitro microvessel tubule 
formation was assessed using a Matrigel endothelial cell tubule 
formation assay. This was modified from a previously reported 
method (23,24). Briefly, 250 µg of Matrigel was seeded, in 
serum-free medium, into a 96-well plate and placed in an incu-
bator for a minimum of 40 min to set. Following this, 35,000 
HECV were seeded onto the Matrigel layer and incubated for 
4-5 h, in the presence or absence of DME25, FAK inhibitor 
or their combination. Tubule formation that occurred over the 
incubation period was visualised under low magnification and 
images captured. Total tubule perimeter per field was quantified 
using ImageJ software.
Cell-matrix adhesion. Cell culture plate (96-well) was first 
coated with 2 µg Matrigel and allowed to air dry. After rehydra-
tion for 1 h, the wells were gently washed with DMEM medium, 
HECV cells (20,000 per well) were added together with the 
respective treatments. Wells were gently washed with BSS 
5 times, before cells were fixed with 4% formalin and stained 
with crystal violet. Adherent cells were counted and shown 
as number of adherent cell per high power field of an upright 
microscope.
Immunofluorescent staining (IFC). HECV cells were seeded 
at a density of 20,000 cells per well in a 16-well chamber 
slide (LAB-TEK Fisher Scientific UK, Longhborough, UK), 
together with the respective treatment for 2 h (25,26). Medium 
was carefully aspirated from the wells and the cells were fixed 
in 4% formalin for 20 min. Following fixation, the cells were 
permeabilised for 5 min in a 0.1% Triton X-100 BSS solu-
tion. A blocking solution of (Tris buffer 25 mM Tris, pH 7.4) 
with 10% semi-skimmed milk was used to block non-specific 
binding for 40 min. Cells were subsequently washed twice 
with wash buffer before probing for specific antibodies to 
FAK and phopho-FAK (SC-1688 and SC-11766, respectively, 
from Santa-Cruz Biotechnologies, Inc., Santa Cruz, CA, USA). 
Primary antibodies were made up in the Tris buffer with 3% 
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milk at a 1:100 concentration for 1 h. The primary antibody 
was then completely removed by washing the cells 5 times in 
the same buffer. FITC conjugated anti-mouse and anti-rabbit 
secondary antibodies (Sigma-Aldrich) was subsequently added 
to the cells and the slides were incubated on a shaker platform 
in the dark for 1 h. The slides were finally washed 3 times to 
remove unbound secondary antibody, mounted with Fluor-save 
(Calbiochem-Novabiochem Ltd., Nottingham, UK) and visual-
ised under an Olympus BX51 fluorescent microscope at x100 
objective magnification.
SDS-PAGE and western blotting. Cells were grow to confluence 
in a 25 cm3 tissue culture flask, detached and lysed in HCMF 
buffer containing 1% Triton X-100, 2 mM CaCl2, 100 µg/ml 
phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml 
aprotinin and, 10 mM sodium orthovanadate on a rotor wheel 
for 1 h before being spun at 13,000 x g to remove insolubles. 
The protein levels in the samples were subsequently quantified 
using the Bio-Rad DC Protein assay kit (Bio-Rad Laboratories, 
CA, USA).
Once sufficient separation had occurred the proteins were 
blotted onto a Hybond-C Extra nitrocellulose membrane 
(Amersham Biosciences UK Ltd., Bucks, UK), blocked in 
10% milk and probed for the expression of specific proteins. 
Anti-pFAK and anti-pPaxillin were used to probe the 
phophorylated FAK and paxillin, respectively (27). In addition 
to this, GAPDH expression was also assessed using an anti-
body specific to this molecule (Santa Cruz Biotechnology Inc.) 
to assess total protein levels and uniformity throughout the 
test samples. Protein bands were then visualised through the 
Supersignal West Dura Extended Duration substrate chemilu-
minescent system (Perbio Science UK Ltd., Cramlington, UK) 
and detected using a UVIProChem camera system (UVItec 
Ltd., Cambridge, UK).
Results
DME25 inhibited formation of microvessel-like tubules without 
affecting the growth of endothelial cells. Using an in vitro tubule 
formation assay, it was shown that DME25 (shown in Fig. 1 are 
1:1000 dilution) significantly reduced tubule length compared 
with control (p=0.046). This was seen at concentrations at 
which no growth inhibition was achieved at the concentrations 
without cytotoxicity on HECV cells (Fig. 2). DME25 over a 
Figure 1. Effects of DME25 on in vitro microvessel tubule formation from HECV cells. HECV cells were sandwiched between Matrigel layers and treated with 
either medium as control (A), with FAK inhibitor (25 nM) (B), with DME25 (1:2,000) (C) or the combination FAK inhibitor and DME25 (D). Tubules are shown 
as images from inverted microscope (A-D) and as quantified length (E) using digital image analysis. DME25 significantly inhibited tubule forming and had a 
synergistic effect with FAK inhibitor.
Figure 2. DME25 had little impact of the in vitro growth of endothelial cells. 
Cells were treated with DME25 at difference dilution for 72 h. Cells num-
bers were evaluated using crystal violet. There was no significant effect on the 
growth of HECV cells. 
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wide concentration did not have a significant influence on the 
growth of endothelial cells.
DME25 exerted an inhibitory effect on cell-matrix adhesion. 
DME25 demonstrated a concentration-dependent inhibitory 
effect on the adhesion of HECV cells, with marked inhibitory 
effects seen at dilutions of 1:5,000 or lower (Figs. 3A and 4). 
Using 3D modelling, it was seen that the inhibitory effects by 
DME25 were seen across the frequencies tested (Figs. 3B and 
5). Using conventional cell-matrix adhesion method, DME25 
had a significant inhibitory effect on the adhesion (Fig. 3C 
and D).
Figure 4. DME25 and cell adhesion at a concentration-dependent matter (A) and is dependent on FAK pathway (B). Shown are data obtained from cell Rb modelling. 
Figure 3. (A and B) Concentration-dependent inhibition of the matrix adhesion of HECV cells by DME25. DME25 was diluted from 1:40 to 1:125,000 (A). 
Dilutions below 1:25,000 showed inhibitory effect. (B) 3D imaging of the adhesion. Left, control; right, cells with DME25 at 1:1,000. X-axis, frequencies; Y-axis, 
resistance; Z-axis, time. (C and D) Cell-matrix adhesion investigated by conventional method. (C) Images from crystal violet stained adherence cells; (D) number 
of adherent cell per high power field. *p<0.01 vs control; #p<0.01 vs DME alone and FAK inhibitor alone.
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Endothelial cell migration was reduced by DME25. In a similar 
fashion to cell-matrix adhesion, cellular migration was similarly 
inhibited by the presence of DME25 and was further inhibited 
when FAK inhibitor was used together with DME25 (Fig. 6).
DME25 and FAK inhibitor had a synergistic effect on the 
adhesion, migration and tubule formation of endothelial cells. 
FAK inhibitor has a marked effect on the adhesion of HECV 
cells (Figs. 3C and D, 4B, 5). When administered together with 
DME25, the inhibitory effect appears to be synergistically 
strengthened as seen in these figures.
FAK inhibitor appears to have an inhibitory effect on tubule 
formation although this is not statistically significant (p=0.14) 
(Fig. 1E). However, the combination between DME25 and 
FAK inhibitor had a marked inhibition on tubule formation, 
compared with control, with FAK inhibitor along and DME25 
along (p=0.006, p=0.041, p=0.011, respectively).
DME25 inhibited phosphorylation of FAK in endothelial cells. 
We further evaluated the effect of DME25 on the activation of 
FAK and paxillin in HECV cells, namely tyrosine phophory-
lation in these proteins, using phospho-tyrosine specific 
antibodies. As shown in Fig. 7, DME25 suppressed phosphory-
lation of FAK and produced more profound inhibition together 
with FAK inhibitor. Neither DME25 nor FAK inhibitor or their 
combinations had marked effect on the phosphorylation of 
paxillin.
Using immunofluorescence method, FAK was seen to be 
stained strongly in control cells at the focal adhesion sites 
(Fig. 8, left panel, indicated by arrows). Addition of DME25, 
FAK inhibitor and the combination of DMA25 and FAK inhib-
itor render the cells with less focal adhesion complex although 
the degree of staining was unchanged compared with control 
(Fig. 8, left panel). It is very interesting to observe the marked 
changes of phosphorylated FAK which was stained with phos-
phorylation specific anti-pFAK antibody. As shown in Fig. 8 
(right panel, with extended exposure time), control cells had 
visible stainings of pFAK at the focal adhesion sites in control 
cells. Both DME25 and FAK inhibitor resulted in reduction of 
staining of pFAK. However, cells treated with the combination 
of DME25 and FAK inhibitor almost completely lost staining 
of pFAK (Fig. 8 right panel).
Figure 5. The inhibitory effect of DME25 and the role of FAK. DME25 marked 
reduced the adhesion, an effect was further strengthened by FAK inhibitor 
as shown by both the migration trace (A) and 3D modelling (B). (i) Control; 
(ii) cells treated with FAK inhibitor (25 nM); (iii) cells treated with DME25 
(1:1000) and (iv) cells treated with a combination of (ii) and (iii). X-axis, fre-
quencies; Y-axis, resistance; Z-axis, time.
Figure 6. The inhibitory effect on cell migration by DME25 and the role of 
FAK. DME25 marked reduced the migration, an effect was further strengthened 
by FAK inhibitor as shown by both the migration trace (A) and 3D modelling 
(B). (i) Control; (ii) cells treated with FAK inhibitor (25 nM); (iii) cells treated 
with DME25 (1:1,000) and (iv) cells treated with a combination of (ii) and (iii). 
X-axis, frequencies; Y-axis, resistance; Z-axis, time. Arrow in A indicates the 
time point at which electric wounding was conducted.
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Discussion
Anti-angiogenesis therapies, for example Avastin, have now been 
used as new line of therapies in solid tumours and have been 
shown to have their clinical worthiness in some tumour types. 
A few of the traditional anti-cancer compounds have also been 
found to have their role in anti-angiogenesis. Yangzheng Xiaoji 
is a new formula developed from traditional Chinese medicine 
and has been shown to have clinical benefit in patients with 
cancers, namely liver cancer and gastric cancer, two of the 
leading cancer types in China (10,11). The precise mechanism(s) 
of the formula is not clear, although there has been indication 
that it may have some immune protective effects when admin-
istered during chemotherapy. However, in a recent preliminary 
study (17), Yangzheng Xiaoji has been shown to have an inhibi-
tory effect on the adhesion and migration of cancer cells. These 
two cell functions are also critical during the angiogenic process 
of endothelial cells.
The present study attempted to examine the potential effect 
of Yangzheng Xiaoji on angiogenesis. Our initial screening met 
with a surprising finding that extract from Yangzheng Xiaoji, 
DME25 markedly inhibited in vitro tubule formation from 
vascular endothelial cells. We further demonstrated that the 
Figure 8. Immunofluorescence staining of focal adhesion kinase (FAK) and phospho-FAK in HECV cells. 20,000 HECV cells were added together with medium 
as control, DME25 (1:1,000), FAK inhibitor or the combination of DME25 and FAK inhibitor. Cells were washed and fixed after 2 h. Total FAK (left panel) and 
phosphorylated FAK (right) were stained, respectively, using anti-FAK and anti-pFAK antibodies. Images for FAK was obtained with 100 msec exposure and that 
of pFAK 400 msec.
Figure 7. DME25 suppressed phosphorylation of FAK and paxillin in HECV 
endothelial cells. After serum starvation for 2 h, HECV cells were treated with 
DME25 (at two different concentrations, namely 1:1,000 and 1:5,000 dilutions), 
FAK inhibitor (25 nM) or their combination for 60 min. After separation of the 
equal amount of proteins on SDS PAGE gels, phosphorylated FAK and paxillin 
were probed using phospho-specific antibodies to FAK and paxillin.
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extract has a concentration-dependent inhibitory effect on 
cell-matrix adhesion and cellular migration. These results 
are interesting and appear to be connected. Cell-matrix adhe-
sion is an important part during cellular migration and both 
the adhesion and migration are essential during angiogenesis 
and in particular during tubule formation in the model of the 
present study, namely sandwich based tubule formation assay. 
Orchestrated adhesion to matrix and migration over matrix are 
necessary for the endothelial cells to join and form vessel-like 
tubules. Thus, it is plausible to suggest that the effect on adhe-
sion and migration is likely to be the key contributing factor to 
the inhibition on tubule formation.
The other interesting finding of the present study is 
that blocking FAK using a small FAK inhibitor markedly 
strengthened the effect of Yangzheng Xiaoji extract and that 
the extract itself has an inhibitory effect on the activation 
of FAK, namely tyrosine phosphorylation of FAK, which 
was seen by both western blotting and immunofluorescence 
methods. FAK pathway is essential during cell-matrix adhe-
sion and cellular adhesion over extracellular matrix (27-30). 
Upon interacting with matrix, cells utilise the membrane inte-
grins to bind to the matrix and trigger the activation of series 
intracellular events, one of the key pathway is the activation 
of focal adhesion kinase, which in turn leads to activating the 
integrin interaction with the cytoskeletal system (31). This 
forms an essential component during matrix adhesion and 
subsequent cell migration. FAK has been shown to be amongst 
key signalling pathways during angiogenesis (31-35). FAK 
inhibitors, such as the one used in the present study, has been 
shown in early clinical trials to have anti-cancer effects in 
patients with lung cancer and breast cancer (36-40). Extract 
from herbs has been previously shown to affect the activities 
of FAK in endothelial cells (41,42). Together, it can be argued 
that one of the key pathways that Yangzheng Xiaoji targets is 
FAK pathway during the angiogenic process. However, these 
results should be interpreted with caution for the following 
reasons. First, Yangzheng Xiaoji is a mixture of herbal 
medicine. The active ingredient(s) in the formula is yet to 
be found. The effect seen in the present study may well be 
a mixed effect of the extract. Second, angiogenesis requires 
a great deal more coordination of endothelial cells, than cell 
adhesion and cellular migration. Effects on other cellular 
events should also be examined.
In conclusion, the anti-cancer traditional formula, 
Yangzheng Xiaoji, has a profound effect on angiogenesis, in vitro. 
This is seen together with the reduction of cell-matrix adhesion 
and cellular migration and is likely to be mediated by the focal 
adhesion kinase (FAK) pathway.
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